Dynavax makes Christine Larson CFO
This article was originally published in Scrip
Executive Summary
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases, has appointed Christine Larson vice-president and chief financial officer. Ms Larson has a background in corporate finance and investment banking, and joins Dynavax from PDL Biopharma where she was responsible for leading financial and strategic planning, accounting and treasury.